Copyright
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Nov 15, 2019; 11(11): 1021-1030
Published online Nov 15, 2019. doi: 10.4251/wjgo.v11.i11.1021
Published online Nov 15, 2019. doi: 10.4251/wjgo.v11.i11.1021
Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer
Se Jun Park, Hyunho Kim, Kabsoo Shin, Myung Ah Lee, Division of Medical Oncology, Department of Internal Medicine, The Catholic University of Korea, Seoul St. Mary’s Hospital, Seoul 100744, South Korea
Tae Ho Hong, Department of General Surgery, The Catholic University of Korea, Seoul St. Mary’s Hospital, Seoul 100744, South Korea
Author contributions: All authors helped to perform the research; Park SJ was involved with manuscript writing, drafting conception and design, acquisition of data, performing procedures and data analysis; Kim HH, Shin KS, Hong TH contributed to writing the manuscript; Lee MA contributed to writing the manuscript, drafting conception and design, performing procedures and data analysis.
Institutional review board statement: This study was reviewed and approved by the Ethics Committee of The Catholic University of Korea, Seoul St. Mary’s Hospital.
Informed consent statement: Patients were not required to give informed consent for the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: All authors declare no conflict-of-interest related to this research.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Myung Ah Lee, MD, PhD, Professor, Division of Medical Oncology, Department of Internal Medicine, Cancer research institute, College of Medicine, The Catholic University of Korea, Seoul St. Maryâs Hospital, 222 Banpo-daero, Secho-gu, Seoul 100744, South Korea. angelamd@catholic.ac.kr
Telephone: +82-2-22586044 Fax: +82-2-5993589
Received: May 20, 2019
Peer-review started: May 23, 2019
First decision: July 31, 2019
Revised: September 3, 2019
Accepted: September 12, 2019
Article in press: September 13, 2019
Published online: November 15, 2019
Peer-review started: May 23, 2019
First decision: July 31, 2019
Revised: September 3, 2019
Accepted: September 12, 2019
Article in press: September 13, 2019
Published online: November 15, 2019
Core Tip
Core tip: To date, there is no standard regimen for patients with gemcitabine-refractory pancreatic cancer with poor performance status. In this study, we compared the efficacy and toxicity of capecitabine and S-1 for such patients. The median progression free survival was longer in the S-1 group than in the capecitabine group; however, there were no statistical differences in their overall survival. Among grade 3 or 4 toxicity, hand-foot syndrome was significantly more common in the capecitabine group than in the S-1 group. Thus, oral chemotherapy can be considered as a second-line treatment in gemcitabine-refractory pancreatic cancer patients with poor performance status.